Alpha Tau Medical (DRTS) investor relations material

Technology and treatment overview

• Developed a unique method to deliver alpha radiation directly into tumors, aiming for efficient tumor destruction while sparing healthy tissue.

• Demonstrated broad applicability across about 20 tumor types in animal studies, with evidence of immune system activation.

• Uses radium-224 coated metal sources to release alpha-emitting isotopes, achieving a controlled and effective radiation range within tumors.

• Achieves tumor coverage with minimal radiation exposure to surrounding tissue, allowing procedures in standard rooms without heavy shielding.

Clinical progress and trial updates

• Pivotal U.S. trial for recurrent cutaneous squamous cell carcinoma (SCC) is expected to complete recruitment by year-end, with data anticipated mid-2026.

• Achieved 100% complete response rate in a pilot skin cancer study, with only mild to moderate local side effects.

• Received approval in Israel for SCC of the skin/oral cavity and awaiting regulatory feedback in Japan for head and neck cancer.

• Initiated U.S. pilot study in pancreatic cancer after promising survival data, with first patient treated recently.

• IDE approval obtained for a U.S. glioblastoma study, with first patient expected later in 2025.

Combination therapy and immune response

• Evidence suggests local alpha radiation may catalyze systemic immune responses, potentially aiding in metastatic disease control.

• Early combination studies with Keytruda (pembrolizumab) in metastatic head and neck cancer showed higher response rates than historical controls.

• Notable case: a 94-year-old patient experienced complete systemic response after combination therapy, remaining disease-free for over two years.

• Ongoing discussions with the FDA to expand combination studies in the U.S.